Skip to Main content Skip to Navigation
Journal articles

Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial

Abstract : Objectives: To assess long-term efficacy of tocilizumab in treatment-naive patients with Takayasu arteritis (TAK). Methods: Prospective open-labeled trial in naïve patients with TAK who received steroids at the dose of 0.7 mg/kg/day and 7 infusions of 8 mg/kg/month of tocilizumab. The primary endpoint was the number of patients who discontinued steroids after 7 infusions of tocilizumab. Secondary endpoints included disease activity and the number of relapses during 18-month follow-up. Results: Thirteen patients with TAK were included, with a median age of 32 years [19-45] and 12 (92%) females. Six (54%) patients met the primary end-point. A significant decrease of disease activity was observed after 6 months of tocilizumab therapy: decrease of median NIH scale (3 [3, 4] at baseline, versus 1 [0-2] after 6 months; p < 0.001), ITAS-2010 score (5 [2-7] versus 3 [0-8]; p = 0.002), and ITAS-A score (7 [4-10] versus 4 [1-15]; p = 0.0001)]. During the 12-month follow-up after tocilizumab discontinuation, a relapse occurred among 5 patients (45%) out of 11 in which achieved remission after 6 months of tocilizumab. Conclusion: Tocilizumab seems an effective steroid sparing therapy in TAK, but maintenance therapy is necessary.
Document type :
Journal articles
Complete list of metadatas

Cited literature [23 references]  Display  Hide  Download

https://hal.sorbonne-universite.fr/hal-02975571
Contributor : Gestionnaire Hal-Su <>
Submitted on : Thursday, October 22, 2020 - 6:04:47 PM
Last modification on : Tuesday, November 10, 2020 - 4:50:58 PM

File

s13075-020-02311-y.pdf
Publication funded by an institution

Identifiers

Citation

Arsene Mekinian, David Saadoun, Eric Vicaut, Sara Thietart, Bertrand Lioger, et al.. Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial. Arthritis Research and Therapy, BioMed Central, 2020, 22 (1), pp.218. ⟨10.1186/s13075-020-02311-y⟩. ⟨hal-02975571⟩

Share

Metrics

Record views

41

Files downloads

32